Abstract
Testing for activating genomic mutations is recommended in all patients with advanced non-small cell lung cancer (aNSCLC), including ALK, BRAF, KRAS, EGFR, ROS1, as well as PD-L1 expression, to support optimal treatment decisions. Current real-world testing patterns of biomarkers in aNSCLC are not well known and testing rates may be lower than expected despite clinical guideline recommendations. The objective of this study was to measure real-world aNSCLC biomarker testing rates and characterize patient and clinical characteristics associated with testing.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
